RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland

DMM Disease Models and Mechanisms

Volumn 7, Issue 5, 2014, Pages 525-534

  McDonald, Laura ^a   Ferrari, Nicola ^a   Terry, Anne ^b   Bell, Margaret ^b   Mohammed, Zahra M ^b   Orange, Clare ^c   Jenkins, Alma ^b   Muller, William J ^d   Gusterson, Barry A ^c   Neil, James C ^b   Edwards, Joanne ^b   Morris, Joanna S ^b   Cameron, Ewan R ^b   Blyth, Karen ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Mammary development; RUNX2; Transgenic model

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; DNA BINDING PROTEIN; ELF5 PROTEIN, MOUSE; RUNX2 PROTEIN, HUMAN; RUNX2 PROTEIN, MOUSE; STAT5 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL DIFFERENTIATION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LACTATION DISORDER; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TRANSCRIPTION FACTOR RUNX2 GENE; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CLASSIFICATION; HYPERPLASIA; LACTATION; METABOLISM; MIDDLE AGED; MOUSE MAMMARY TUMOR ONCOVIRUS; PARITY; PATHOLOGY; PHYSIOLOGY; PRECANCER; PREGNANCY; TRANSGENIC MOUSE; TRIPLE NEGATIVE BREAST CANCER; UDDER;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYPERPLASIA; LACTATION; MAMMARY GLANDS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE, TRANSGENIC; MIDDLE AGED; PARITY; PRECANCEROUS CONDITIONS; PREGNANCY; STAT5 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84900432506     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.015040     Document Type: Article

References (49)

1. Altman, D. G., McShane, L. M., Sauerbrei, W. and Taube, S. E. (2012). Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 10, 51.
2. Barnes, G. L., Javed, A., Waller, S. M., Kamal, M. H., Hebert, K. E., Hassan, M. Q., Bellahcene, A., Van Wijnen, A. J., Young, M. F., Lian, J. B. et al. (2003). Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 63, 2631-2637. (Pubitemid 36605206)
3. Barnes, G. L., Hebert, K. E., Kamal, M., Javed, A., Einhorn, T. A., Lian, J. B., Stein, G. S. and Gerstenfeld, L. C. (2004). Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 64, 4506-4513. (Pubitemid 38856922)
4. Blyth, K., Terry, A., Mackay, N., Vaillant, F., Bell, M., Cameron, E. R., Neil, J. C. and Stewart, M. (2001). Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20, 295-302. (Pubitemid 32142318)
5. Blyth, K., Cameron, E. R. and Neil, J. C. (2005). The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 5, 376-387. (Pubitemid 40637829)
6. Blyth, K., Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J. C. and Cameron, E. R. (2006). Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 66, 2195-2201.
7. Blyth, K., Slater, N., Hanlon, L., Bell, M., Mackay, N., Stewart, M., Neil, J. C. and Cameron, E. R. (2009). Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol. Dis. 43, 12-19.
8. Blyth, K., Vaillant, F., Jenkins, A., McDonald, L., Pringle, M. A., Huser, C., Stein, T., Neil, J. and Cameron, E. R. (2010). Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol. Dis. 45, 117-123.
9. Boulanger, C. A., Wagner, K. U. and Smith, G. H. (2005). Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 24, 552-560. (Pubitemid 40188560)
10. Cameron, E. R. and Neil, J. C. (2004). The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 23, 4308-4314. (Pubitemid 38758596)
11. Castilla, L. H., Perrat, P., Martinez, N. J., Landrette, S. F., Keys, R., Oikemus, S., Flanegan, J., Heilman, S., Garrett, L., Dutra, A. et al. (2004). Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 101, 4924-4929. (Pubitemid 38469179)
12. Chimge, N. O. and Frenkel, B. (2013). The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 32, 2121-2130.
13. Chimge, N. O., Baniwal, S. K., Little, G. H., Chen, Y. B., Kahn, M., Tripathy, D., Borok, Z. and Frenkel, B. (2011). Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 13, R127.
14. Chimge, N. O., Baniwal, S. K., Luo, J., Coetzee, S., Khalid, O., Berman, B. P., Tripathy, D., Ellis, M. J. and Frenkel, B. (2012). Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin. Cancer Res. 18, 901-911.
15. Choi, Y. S., Chakrabarti, R., Escamilla-Hernandez, R. and Sinha, S. (2009). Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev. Biol. 329, 227-241.
16. Chuang, L. S. and Ito, Y. (2010). RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29, 2605-2615.
17. Das, K., Leong, D. T., Gupta, A., Shen, L., Putti, T., Stein, G. S., van Wijnen, A. J. and Salto-Tellez, M. (2009). Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur. J. Cancer 45, 2239-2248.
18. Ferrari, N., McDonald, L., Morris, J. S., Cameron, E. R. and Blyth, K. (2013). RUNX2 in mammary gland development and breast cancer. J. Cell. Physiol. 228, 1137-1142.
19. Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S. et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76.
20. Inman, C. K. and Shore, P. (2003). The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem. 278, 48684-48689. (Pubitemid 41079508)
21. Inman, C. K., Li, N. and Shore, P. (2005). Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol. Cell. Biol. 25, 3182-3193. (Pubitemid 40464320)
22. Javed, A., Barnes, G. L., Pratap, J., Antkowiak, T., Gerstenfeld, L. C., van Wijnen, A. J., Stein, J. L., Lian, J. B. and Stein, G. S. (2005). Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Natl. Acad. Sci. USA 102, 1454-1459. (Pubitemid 40209191)
23. Kendrick, H., Regan, J. L., Magnay, F. A., Grigoriadis, A., Mitsopoulos, C., Zvelebil, M. and Smalley, M. J. (2008). Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9, 591.
24. Khalid, O., Baniwal, S. K., Purcell, D. J., Leclerc, N., Gabet, Y., Stallcup, M. R., Coetzee, G. A. and Frenkel, B. (2008). Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 149, 5984-5995.
25. Kilbey, A., Blyth, K., Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E. R. and Neil, J. C. (2007). Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 67, 11263-11271. (Pubitemid 350248552)
26. Kirkegaard, T., Edwards, J., Tovey, S., McGlynn, L. M., Krishna, S. N., Mukherjee, R., Tam, L., Munro, A. F., Dunne, B. and Bartlett, J. M. (2006). Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48, 787-794. (Pubitemid 43800937)
27. Komori, T. (2010). Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 339, 189-195.
28. Lau, Q. C., Raja, E., Salto-Tellez, M., Liu, Q., Ito, K., Inoue, M., Putti, T. C., Loh, M., Ko, T. K., Huang, C. et al. (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 66, 6512-6520. (Pubitemid 44085605)
29. Liu, X., Robinson, G. W., Wagner, K. U., Garrett, L., Wynshaw-Boris, A. and Hennighausen, L. (1997). Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179-186. (Pubitemid 27081895)
30. Mangan, J. K. and Speck, N. A. (2011). RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit. Rev. Oncog. 16, 77-91.
31. Mohammed, Z. M., Edwards, J., Orange, C., Mallon, E., Doughty, J. C., McMillan, D. C. and Going, J. J. (2012a). Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology 61, 283-292.
32. Mohammed, Z. M., Going, J. J., Edwards, J., Elsberger, B., Doughty, J. C. and McMillan, D. C. (2012b). The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br. J. Cancer 107, 864-873.
33. Mohammed, Z. M., Going, J. J., McMillan, D. C., Orange, C., Mallon, E., Doughty, J. C. and Edwards, J. (2012c). Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology 61, 675-684.
34. Molyneux, G., Geyer, F. C., Magnay, F. A., McCarthy, A., Kendrick, H., Natrajan, R., Mackay, A., Grigoriadis, A., Tutt, A., Ashworth, A. et al. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403-417.
35. Nagaraja, G. M., Othman, M., Fox, B. P., Alsaber, R., Pellegrino, C. M., Zeng, Y., Khanna, R., Tamburini, P., Swaroop, A. and Kandpal, R. P. (2006). Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25, 2328-2338.
36. Oakes, S. R., Naylor, M. J., Asselin-Labat, M. L., Blazek, K. D., Gardiner-Garden, M., Hilton, H. N., Kazlauskas, M., Pritchard, M. A., Chodosh, L. A., Pfeffer, P. L. et al. (2008). The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev. 22, 581-586. (Pubitemid 351342431)
37. Onodera, Y., Miki, Y., Suzuki, T., Takagi, K., Akahira, J., Sakyu, T., Watanabe, M., Inoue, S., Ishida, T., Ohuchi, N. et al. (2010). Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci. 101, 2670-2675.
38. Place, A. E., Jin Huh, S. and Polyak, K. (2011). The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 13, 227.
39. Pratap, J., Javed, A., Languino, L. R., van Wijnen, A. J., Stein, J. L., Stein, G. S. and Lian, J. B. (2005). The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol. Cell. Biol. 25, 8581-8591. (Pubitemid 41369178)
40. Pratap, J., Wixted, J. J., Gaur, T., Zaidi, S. K., Dobson, J., Gokul, K. D., Hussain, S., van Wijnen, A. J., Stein, J. L., Stein, G. S. et al. (2008). Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68, 7795-7802.
41. Pratap, J., Imbalzano, K. M., Underwood, J. M., Cohet, N., Gokul, K., Akech, J., van Wijnen, A. J., Stein, J. L., Imbalzano, A. N., Nickerson, J. A. et al. (2009). Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res. 69, 6807-6814.
42. Pratap, J., Lian, J. B. and Stein, G. S. (2011). Metastatic bone disease: role of transcription factors and future targets. Bone 48, 30-36.
43. Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M. L., Wu, L., Lindeman, G. J. and Visvader, J. E. (2006). Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88. (Pubitemid 43053633)
44. Shore, P. (2005). A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J. Cell. Biochem. 96, 484-489.
45. Stewart, M., Terry, A., Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., Onions, D. E. and Neil, J. C. (1997). Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA 94, 8646-8651. (Pubitemid 27335093)
46. Swiers, G., de Bruijn, M. and Speck, N. A. (2010). Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int. J. Dev. Biol. 54, 1151-1163.
47. Vaillant, F., Blyth, K., Terry, A., Bell, M., Cameron, E. R., Neil, J. and Stewart, M. (1999). A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 18, 7124-7134. (Pubitemid 30028884)
48. Wagner, K. U., Boulanger, C. A., Henry, M. D., Sgagias, M., Hennighausen, L. and Smith, G. H. (2002). An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 129, 1377-1386. (Pubitemid 34874159)
49. Wang, L., Brugge, J. S. and Janes, K. A. (2011). Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc. Natl. Acad. Sci. USA 108, E803-E812.